Pharmala to supply merhavim mental health centre clinical trial in exchange for full data license, in partnership with maps israel

Toronto, jan. 20, 2025 (globe newswire) -- pharmala biotech holdings inc. (“pharmala” or the “company”) (cse: mdma) (otc:mdxxf), a biotechnology company focused on the research, development, and manufacturing of laneo™ mdma and novel derivatives of mdma (mdxx class molecules), is pleased to announce that it has executed an agreement with merhavim mental health centre of beer yaakov, israel (“merhavim”). all data generated in the clinical trial, entitled “mdma assisted psychotherapy for ptsd of early sexual trauma compared to all trauma in adulthood”, will be licensed to pharmala for regulatory and commercial purposes in exchange for the clinical trial material, which will be provided by pharmala on a zero-cost basis.
MAPS Ratings Summary
MAPS Quant Ranking